ArticleThe Journal of investigative dermatology2026
Proteomic approaches for interrogating kinase signaling networks.
Article in The Journal of investigative dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Kinases are central regulators of multiple signaling cascades, controlling processes such as cellular growth, proliferation, and differentiation. Given their vital role within the cell, dysregulated kinase activity contributes to several skin diseases, including melanoma and dermatitis. Poor disease response or resistance to targeted inhibitors can be driven by adaptive kinase responses. Genomic assays are highly informative but do not accurately capture kinase abundance and activity at the protein level. In this paper, we review 2 complementary mass spectrometry-based proteomics methods for functional kinome analysis that are readily applicable to dermatology research. Multiplexed inhibitor beads coupled with mass spectrometry (MIB-MS) uses broad-spectrum, immobilized kinase inhibitors to enrich for kinases in active conformation, providing an unbiased, pathway-level readout of kinase network dynamics, adaptive rewiring, and drug specificity. Internal standard triggered-parallel reaction monitoring (IS-PRM)-targeted proteomics, including the Thermo SureQuant acquisition method, leverages heavy peptide triggers to deliver sensitive, consistent quantification of predefined kinase peptides from limited input clinical specimens, including formalin fixed, paraffin embedded. We summarize optimized workflows, instrument set-up, sample requirements, technical considerations, and limitations. Together, MIB-MS and IS-PRM SureQuant offer orthogonal, scalable strategies to profile kinase networks in skin biology and to inform target discovery, biomarker development, and rational therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.